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ABSTRACT
Introduction: Antimicrobial drugs are known to have effects on the human gut microbiota. We 
studied the long-term temporal relationship between several antimicrobial drug groups and the 
composition of the human gut microbiota determined in feces samples.
Methods: Feces samples were obtained from a community-dwelling cohort of middle-aged and 
elderly individuals (Rotterdam Study). Bacterial DNA was isolated and sequenced using V3/V4 16 S 
ribosomal RNA sequencing (Illumina MiSeq). The time between the last prescription of several 
antimicrobial drug groups and the day of sampling was categorized into 0–12, 12–24, 24–48 and 
>48 months. The effects of the antimicrobial drug groups on the Shannon alpha-diversity (diver-
sity), the Bray–Curtis beta-diversity (community structure), the Firmicutes/Bacteroidetes (F/B) ratio 
and individual genera were determined.
Results: We studied the gut microbiota of 1413 individuals (57.5% female, median age 62.6 years). 
The alpha-diversity was significantly lower up to 4 years after prescriptions of macrolides and 
lincosamides. It was also lower in the first year after the use of beta-lactams. The community 
structure (beta-diversity) of the microbiota was significantly different up to 4 years for macrolides 
and lincosamides, the first year for beta-lactams and at least the first year for quinolones. For the F/B 
ratio, drugs with a high anaerobic activity shifted the ratio toward Firmicutes in the first year 
whereas other antimicrobial drugs shifted the ratio toward Bacteroidetes.
Conclusion: Use of antimicrobial drugs is associated with a shift in the composition of the gut 
microbiota.These effects differ in strength and duration, depending on the antimicrobial drug group 
used. These findings should be considered when prescribing antimicrobial drugs.
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The gut microbiota plays a role in a variety of 
processes, such as protection against overgrowth 
of pathogenic micro-organisms, in the develop-
ment of the host immune response, in neurologic 
signaling and in the synthesis and metabolism of 
several compounds, such as short-chain fatty acids 
(SCFAs).1,2 In particular, the SCFA butyrate is said 
to have an important function in the maintenance 
of a healthy colonic epithelium.3
The composition of the gut microbiota may differ 
with age,4 gender and BMI5 and can change under 
the influence of diet,6,7 physical activity,8 diabetes9 
and use of drugs, such as proton pump inhibitors,10 
corticosteroids11 and statins.12 Furthermore, it is 
known that it can be influenced by the use of anti-
microbial drugs (post-antibiotic dysbiosis). The use 
of antimicrobial drugs has been reported to increase 
the vulnerability to overgrowth of potentially patho-
genic bacteria, such as Clostridium difficile, with the 
risk of pseudomembranous colitis. Moreover, it has 
been described to cause a loss of diversity of the gut 
microbiota, cause a decrease of important taxa, alter 
gene expression, select for intrinsically resistant bac-
teria, and select for new mutations.13–15 
Additionally, dysbiosis has also been designated as 
a factor that promotes horizontal gene transfer, 
thereby increasing the probability of spreading anti-
biotic resistance genes.16
In adults, some information is available about 
the effects of specific antimicrobial drug groups 
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on the composition of the gut microbiota. Short- 
term exposure to clindamycin was shown to cause 
a shift of the gut microbiota, for example a decline 
in the diversity of Bacteroidetes.17 Furthermore, 
Lachnospiraceae abundancy in the gut was 
decreased up to 6 months after the use of amox-
icillin or azithromycin.18 Also, one study showed 
the effects of using beta-lactam antibiotics in the 
12 months before sampling in a population-based 
cohort.19 However, most studies have investigated 
these effects in small populations, studying rather 
short-term effects and using a variety of methods to 
investigate the microbiota. Therefore, the objective 
of this study was to describe and compare the 
effects and the duration of the effects of different 
antimicrobial drug groups on the composition of 
the human microbiota in feces samples from a large 
population of community-dwelling middle-aged 
and elderly individuals using different outcomes 
that characterize the microbiota.
Results
We obtained a dataset with microbiota data from 
1427 participants, of whom 14 (1.0%) were 
excluded, because no pharmacy data were available. 
From the remaining 1413 participants, 812 (57.5%) 
were female and 601 (42.5%) were male with 
a median age of 62.6 years (IQR 58.6–66.1), a med-
ian BMI of 26.8 (IQR 24.5–29.7) and the feces 
sample had been in the mail for a median time of 
1 day (IQR 1–2 days). Furthermore, 323 individuals 
used proton pump inhibitors and 252 used a statin. 
There was no use of tacrolimus and the use of 
antineoplastic agents (3 participants, 0.2%) was 
very low; therefore, these drugs were not included 
in the models. A total of 1281 (90.6%) participants 
had received at least 1 prescription of an antimi-
crobial drug during follow-up (at least 17 years). 
Most participants (73.7%) had 1 or more prescrip-
tions of beta-lactam antibiotics, other frequently 
used antibacterial drugs were tetracyclines (57.7%) 
and macrolides and lincosamides (44.0%). The 
number of prescriptions for amphenicols (J01B), 
other beta-lactam antibacterials (J01D), aminogly-
coside antibacterials (J01G), glycopeptide antibac-
terials (J01XA), polymyxins (J01XB), steroid 
antibacterials (J01XC), imidazole derivatives 
(J01XD) and other antibacterials (J01XX) was very 
low and these groups could not be analyzed sepa-
rately (Table 1). The correlations between the dif-
ferent antimicrobial drug groups were low 
(Table S1).
Shannon alpha-diversity
The median overall diversity was 4.10 (IQR 
3.73–4.37). The strongest and most prolonged 
effect on diversity was seen in the group of the 
macrolides and lincosamides (J01F). 
Transforming the beta’s back to physiological 
values (for an average person) resulted in 
a significantly lower diversity of 0.48 for 
0–12 months after use of macrolides and linco-
samides (J01F); a lower diversity of 0.28 (which 
was not significant when adjusting for all other 
Table 1. Use of antimicrobial drugs in the study population.
Antimicrobial drug group 0–12 months* 12–24 months 24–48 months >48 months None
Antibacterial for systemic use (J01) 355 217 236 473 132
Tetracyclines (J01A) 100 103 152 461 597
Amphenicols (J01B) 0 0 0 0 1413
Beta-lactam antibacterials (J01C) 179 131 163 569 371
Other beta-lactam antibacterials (J01D) 1 2 1 11 1398
Sulfonamides and trimethoprim (J01E) 20 23 55 267 1048
Macrolides, lincosamides and streptogramins (J01F) 62 49 106 405 791
Aminoglycoside antibacterials (J01 G) 1 0 0 1 1411
Quinolone antibacterials (J01 M) 35 38 48 154 1138
Glycopeptide antibacterials (J01XA) 0 0 0 1 1412
Polymyxins (J01XB) 0 0 0 0 1413
Steroid antibacterials (J01XC) 0 0 0 0 1413
Imidazole derivatives (J01XD) 0 0 0 2 1411
Nitrofuran derivatives (J01XE) 76 38 67 121 1111
Other antibacterials (J01XX) 13 3 5 3 1389
Use of antibacterial drugs per group and overall for each time period of prescription to fecal sampling (0–12, 12–24, 24–48, >48 months, or no use). The use of 
amphenicols (J01B), other beta-lactam antibacterials (J01D), aminoglycoside antibacterials (J01G), glycopeptide antibacterials (J01XA), polymyxins (J01XB), 
steroid antibacterials (J01XC), imidazole derivatives (J01XD) and other antibacterials (J01XX) is too low to analyze further. 
*Time period between prescription of antimicrobial drug and fecal sampling.
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antimicrobial drug use) for 12–24 months after 
use, a significantly lower diversity of 0.35 for 
24–48 months after use and a significantly 
lower diversity of 0.17 for 48 months or longer 
after use. We also showed a significantly lower 
diversity of 0.24 after the use of beta-lactam 
antibacterials (J01C) within 1 year before feces 
sampling. No change in diversity was seen after 
the use of tetracyclines (J01A), sulfonamides 
and trimethoprim (J01E), quinolones (J01M) 
and nitrofurans (J01XE). (untransformed 
beta’s of model 2 in Figure 1)
We also classified the antimicrobial drugs in 
antimicrobial drugs with anaerobic activity (con-
sisting of combinations of penicillins, including 
beta-lactamase inhibitors (J01CR), lincosamides 
(J01 FF) and imidazole derivatives (metronidazole) 
(J01XD): anaerobic+) and a group without this 
activity (all other antimicrobial drugs: anaerobic-). 
The use of anaerobic+ antimicrobial drugs was 
associated with a stronger and more prolonged 
effect on diversity than the use of antimicrobials 
without this activity. For an average person, diver-
sity after the use of anaerobic+ antimicrobial drugs 
was 0.51 lower for the 0–12 months period and 0.36 
lower for the 12–24 months period. Diversity was 
only 0.23 lower (for an average person) 
0–12 months after the use of anaerobic- 
antimicrobial drugs. (untransformed beta’s in 
Figure 2) We also performed two sensitivity ana-
lyses with additional adjustment for diet and smok-
ing, which slightly shifted the use of beta-lactams in 
the first year before sampling, resulting in a not 
significant difference. (Fig. S1 and S2)
Firmicutes/Bacteroidetes ratio
The median F/B ratio was 0.085 (IQR 0.037–0.21). 
We could not show any significant differences for 
any of the different antimicrobial drug groups on 
the F/B ratio, both in model 1 and in model 2, in 
which we additionally adjusted for all antimicrobial 
drug use. (untransformed beta’s for model 2 in 
Figure S3). However, the F/B ratio significantly 
shifted toward Firmicutes in the 0–12 months 
before sampling after the use of anaerobic+ anti-
microbial drugs. Furthermore, a significant shift 
could be demonstrated 12–24 months, 
24–48 months and 48 months after the use of 
anaerobic- antimicrobial drugs toward 
Bacteroidetes of respectively 0.18, 0.20 and 0.16. 
(untransformed beta’s in Figure 3).
Community structure
Concerning the community structure (beta- 
diversity), we again found significant differences 
for macrolides and lincosamides (J01F) in all time 
categories. We also found a difference for beta- 
lactams (J01C) in 0–12 months before sampling. 
Finally, we found significant differences for quino-
lones both for 0–12 and 24–48 months before sam-
pling, but not for 12–24 months (Figure 4). Most 
and strongest differences in genera were seen after 
the use of macrolides and lincosamides 
(Supplementary Table 2).
Discussion
In this study, we showed an association between the 
use of different oral antimicrobial drugs and the 
diversity of the gut microbiota in feces samples of 
a middle-aged and elderly community-dwelling 
population. The strongest and most prolonged 
effects on the microbiota diversity were shown for 
macrolides and lincosamides, and these effects 
lasted up to several years after use. Also, diversity 
was lower and community structure was different 
in the first year after beta-lactam use. Furthermore, 
the use of antimicrobial drugs with a high anaero-
bic activity was associated with a shift toward 
Firmicutes. This, in contrary to the use of antimi-
crobial drugs without this activity, which resulted 
in s shift toward Bacteroidetes.
Increasing evidence shows that changes in the 
microbiota by antimicrobial drugs are associated 
with a variety of diseases. A study in Finnish school 
children reported an association between frequent 
macrolide use in early life (<2 years) and the devel-
opment of asthma.20 Furthermore, the use of sev-
eral antimicrobial drug groups was shown to be 
associated with several cancers in a large-nested 
case–control study, possibly acting via the gut 
microbiota.21 Also, but still unproven, it has been 
suggested to prescribe probiotics simultaneously 
with antimicrobial drugs. A large systemic review 
showed that there is evidence that probiotics are 
effective in preventing Clostridium difficile- 
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associated diarrhea in not-immunocompromised 
individuals with a high baseline risk.22 
Furthermore, in mice concurrent probiotics 
treatment during or after antibiotic therapy caused 
suppression of Enterobacteriaceae outgrowth, while 
promoting blooming of Firmicutes.23 Therefore, 
Figure 1. Diversity after antimicrobial drug use. Plots of the beta’s with 95% confidence intervals of the linear regression with as 
dependent variable the transformed (cube) Shannon alpha-diversity and as independent variables the different antimicrobial drug 
groups. All antimicrobial drug groups were analyzed with dummy variables with categories of use of 0–12, 12–24, 24–48 and 
>48 months compared to no use before sampling. The analyses were adjusted for age, sex, BMI, diabetes, time in mail, batch number, 
use of statins, PPIs, SSRIs, antipsychotics and systemic corticosteroids and (categorized) use of all other antimicrobial drugs.
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the influence on the gut microbiota should be taken 
into consideration when prescribing antibiotic 
drugs.
Many studies investigated the microbiota with 
different outcome parameters, included few parti-
cipants or reported only short-term effects.17–19 
A strength of our study is that we studied the gut 
microbiota in a large population-based cohort with 
detailed information on antimicrobial drug pre-
scriptions and over more than a 4-year time period 
using different outcome parameters. Furthermore, 
we adjusted our models for several potential con-
founders, such as sex, age, BMI, diabetes and use of 
co-medication (statins, systemic corticosteroids, 
proton pump inhibitors, SSRIs and antipsychotics). 
Diversity is the most frequently reported outcome 
Figure 2. Diversity after using antimicrobial drugs with high anaerobic activity vs other antimicrobial drugs. Plots of the beta’s with 
95% confidence intervals of the linear regression with as dependent variable the transformed (cube) Shannon alpha-diversity and as 
independent variables the combined antimicrobial drugs that have a strong anaerobic activity (anaerobic + drugs) and the combined 
remaining antimicrobial drugs (anaerobic- drugs). Both were analyzed with dummy variables with categories of 0–12, 12–24, 24–48 
and >48 months compared to no use. The analyses were adjusted for age, sex, BMI, diabetes, time in mail, batch number, use of statins, 
PPIs, SSRIs, antipsychotics and systemic corticosteroids and (categorized) use of all other antimicrobial drugs.
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in microbiota studies and loss of diversity appears 
as the most consistent finding of intestinal 
dysbiosis.24 We also report on the Firmicutes/ 
Bacteroidetes ratio, and the community structure, 
using the beta-diversity. The different outcome 
parameters enable a broader interpretation of the 
effect of antibiotic use on gut microbiota. 
Unfortunately, we could not compare the micro-
biota after with the microbiota before antimicrobial 
drug use, but the time frame, the cohort size and 
the fact that the participants were prescribed anti-
biotics by their physician for an infection and not 
specifically for this study made such a study design 
not feasible. Also, because of the length of the study 
Figure 3. Firmicutes/Bacteroidetes ratio after using antimicrobial drugs with high anaerobic activity vs other antimicrobial drugs. 
Forest plots of the relative risks with 95% confidence intervals of the linear regression with as dependent variable the transformed 
(logarithmic) Firmicutes/Bacteroidetes ratio and as independent variables the combined antimicrobial drugs that have a strong 
anaerobic activity and the combined remaining antimicrobial drugs (“other”). Both were analyzed with dummy variables with 
categories of 0–12, 12–24, 24–48 and >48 months compared to no use. The analyses were adjusted for age, sex, BMI, diabetes, 
time in mail, batch number, use of statins, PPIs, SSRIs, antipsychotics and systemic corticosteroids and (categorized) use of all other 
antimicrobial drugs. A positive beta indicates a shift toward Firmicutes, whereas a negative beta indicates a shift toward Bacteroidetes.
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time, other factors, such as intestinal surgery, could 
also have influenced the microbiota. However, 
because of the size of the cohort, we assume that 
the effect of these factors is small. Another limita-
tion is that the feces was sent to the study center by 
the participants via mail, which might have influ-
enced changes of the microbiota composition by 
environmental factors, such as temperature. 
However, the effects of our collection method 
have been studied and has resulted in the exclusion 
of samples that were in the mail longer than three 
days. Furthermore, the time in the mail was 
included as a covariate in the analyses. Also, the 
microbiota within our cohort had similar profiles as 
those in two other large population-based 
cohorts.25 Another limitation may be that our 
results were obtained from feces samples and may 
not reflect the microbiota more proximal in the 
digestive tract.26 Furthermore, we only used the 
last prescription before sampling, not taking into 
account the antimicrobial drug prescriptions used 
previously. However, we showed that correlations 
between the use of antimicrobial drugs of different 
classes were low and additionally, we adjusted for 
all other antimicrobial drug use.
All our results pointed to macrolides and linco-
samides as the antimicrobial drugs with the highest 
ability to cause changes in the composition of the 
gut microbiota. Of these two types of antibiotics, 
lincosamides such as clindamycin probably have 
the strongest effect, since we also showed that anti-
biotics with a high anaerobic activity (which 
included clindamycin) had strong associations 
with the diversity of the microbiota. Another 
study has also shown long-lasting effects of clinda-
mycin on the gut microbiota but only up to 
2 years.17 Furthermore, the macrolide azithromycin 
was shown to have effects up to 6 months,18 and 
a shift of the gut microbiota at phylum level was 
found in Finnish children of 2–7 years old after 
macrolide use in the 2 years before sampling.20 
Our data indicate that a shift in the composition 
of the gut microbiota persists for a longer time 
period.
Beta-lactam antibiotics caused a lower diversity 
and differences in community structure in the 
first year after use. Beta-lactams have been asso-
ciated with effects on the composition of the gut 
microbiota in several small studies.17 Use of tetra-
cyclines has been associated with a relative increase 
Model 1

















Figure 4. Effects of antimicrobial drug use on community structure. Significance table for all antimicrobial drug groups for all time 
categories studied in model 1, thus adjusted for age, sex, BMI, diabetes, time in mail, batch number, use of statins, PPIs, SSRIs, 
antipsychotics and systemic corticosteroids. (Top) Significance table for all antimicrobial drug groups for all time categories studied in 
model 2, thus adjusted for age, sex, BMI, diabetes, time in mail, batch number, use of statins, PPIs, SSRIs, antipsychotics and systemic 
corticosteroids and (categorized) use of all other antimicrobial drugs. (Bottom) In these significance tables green indicates significant 
(p < 0.05), blue indicates not significant.
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in the abundance of Bacteroidetes.27 Doxycycline 
use was shown to be associated with a lower diver-
sity and a relative increase of Bacteroidetes in 
mice.28 Nitrofurantoin was shown to have only 
minor effects in a study in patients with urinary 
tract infections.29 These studies, however, investi-
gated the effects after a maximum of a few months. 
Since we did not find any effects in our longer time 
periods, this might suggest that the effects of these 
antimicrobial drugs on the gut microbiota are 
restored after a few months. We also did not find 
any effects for sulfonamides and trimethoprim, but 
the use of these drugs (singly or in combination 
products) was very low.
Although we could not find an effect on the F/B 
ratio for separate antimicrobial drug classes, we found 
that the use of antimicrobial drugs with a high anae-
robic activity was associated with a shift toward 
Firmicutes in the first year. In contrast, the use of 
antimicrobial drugs without this anaerobic activity 
was associated with a shift toward Bacteroidetes up 
to several years. Others also described effects on this 
ratio, but only directly after treatment, showing rela-
tively more Bacteroidetes after the use of antimicro-
bial drugs.30,31
In conclusion, we showed that antimicrobial 
drugs, especially macrolides and lincosamides, are 
associated with a long-lasting shift in the gut micro-
biota. Further research is needed to explore the 
interaction and effect of specific antibiotics on the 
gut microbiota, considering the consequences of 




The feces samples that were used in this study were 
obtained from study participants of the third 
cohort (RSIII) of The Rotterdam Study (RS), 
a prospective population-based study. This cohort 
includes 3122 individuals, who were recruited in 
the period March 2012 to June 2014 and who were 
45 years and older, living in the Ommoord district 
in Rotterdam. All participants are invited every 
3–4 years for follow-up interviews and examina-
tions. More detailed information on the Rotterdam 
Study can be found elsewhere.32
Gut microbiota composition
Stool samples were collected at home by the parti-
cipants using a Commode Specimen Collection 
System (Covidien, Mansfield, MA). An aliquot of 
approximately 1 g was transferred to a 25 × 76 mm 
feces collection tube (Minigrip Nederland, Lelystad, 
The Netherlands) and sent through regular mail to 
the Erasmus MC. A short questionnaire addressing 
amongst others date and time of defecation was 
filled out by the participants (response percentage 
69%). After receipt, the samples were stored at −20° 
C. Approximately, 300 mg of feces was homoge-
nized in stool stabilizing buffer. Automated DNA- 
isolation (Arrow DNA; DiaSorin S.p.A., Saluggia, 
Italy) was performed using the Arrow DNA kit 
according to the manufacturer’s instructions and 
included bead-beating in Lysing Matrix B tubes 
containing 0.1 mm silica beads (MP Biomedicals, 
LLC, Bio Connect Life Sciences, Huissen, The 
Netherlands). The hypervariable regions V3 and 
V4 of the (bacterial) 16 S rRNA gene were amplified 
and sequenced using the Illumina MiSeq 2 × 300 
base pairs protocol (FADROSH, PMID: 24558975). 
Phylogenetic multi-sample profiling was performed 
using an in-house developed pipeline based on the 
QIIME 1.9.0 (Caporaso PMID: 20383131) and 
USEARCH version 8.1 (Edgar PMID: 23955772) 
software packages. After subsampling at 10,000 
reads per sample, taxonomy was assigned using 
the naïve Bayesian RDP classifier (vs 2.12)33 and 
the SILVA database (v128; Quast PMID: 
23193283). The OTU table was cleaned by filtering 
out low abundance OTUs (<0.005% of total reads 
per OTUs and OTUs present in <1% of the sam-
ples). Samples with unknown information of time 
in the mail, samples arriving 3 days after collection 
and samples from participants who used antibiotics 
during or just before sampling were removed.
Medication use
The date of the last prescription of an antimicrobial 
drug before feces sampling was obtained from 
a collaborative database of all community pharmacies 
in the Ommoord area that goes back to 
1 January 1995. The antimicrobial drug prescriptions 
were grouped on Anatomical Therapeutic Chemical 
(ATC) code, which included: tetracyclines (J01A), 
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amphenicols (J01B), beta-lactam antibacterials (J01C), 
other beta-lactam antibacterials (J01D) (which 
includes all generations of cephalosporins and carba-
penems), sulfonamides and trimethoprim (J01E), 
macrolides and lincosamides (J01F) (J01F also 
includes streptogramins, but these were not prescribed 
in the study period), aminoglycoside antibacterials 
(J01G), quinolone antibacterials (J01M), glycopeptide 
antibacterials (J01XA), polymyxins (J01XB), steroid 
antibacterials (J01XC), imidazole derivatives 
(J01XD), nitrofuran derivatives (J01XE) and other 
antibacterials (J01XX). For each antimicrobial drug 
group, the time interval between the date of the last 
prescription and feces sampling was calculated and 
categorized into the use of 0–12, 12–24, 24–48 and 
>48 months before sampling or no use of the antimi-
crobial drug group. Additionally, the antimicrobial 
drugs were classified in a group antimicrobial drugs 
with a high activity against anaerobic species (anaero-
bic+), consisting of combinations of penicillins, 
including beta-lactamase inhibitors (J01CR), lincosa-
mides (J01FF) and imidazole derivatives (metronida-
zole) (J01XD) and a group without this activity 
(anaerobic-) (all other antimicrobial drugs).
Confounders
The following potential confounders (at the time of 
feces sampling) were taken into account in the ana-
lyses: age, sex, BMI, diabetes (use of anti-diabetic 
drugs (A10)), use of co-medication, time in the 
mail of the feces sample and batch number repre-
senting two batches of DNA isolation: the first 102 
DNA isolation runs with a relatively high yield were 
labeled 0 and the last 32 runs with a relatively low 
yield were labeled 1. Patients who were prescribed 
a drug within 90 days before feces sampling were 
considered as current user of that drug. Drugs that 
possibly influence the composition of the microbiota 
according to literature: proton pump inhibitors 
(A02BC),10 statins (C10AA),12 systemic corticoster-
oids (H02),11 antipsychotics (N05A),34 selective ser-
otonin reuptake inhibitors (SSRIs) (N06AB),35 
antineoplastic agents (L01),36 and tacrolimus 
(L04AD).37 Since proton pump inhibitors may have 
been sold over the counter, participants were also 
asked if they used proton pump inhibitors.
Other potential confounders for studying the asso-
ciation with the gut microbiota are diet and smoking. 
Adjustment for diet was performed by adjusting for 
the dietary guidelines score (DGS), which is a score 
that varies from 0 to 14 and represents the adherence 
to the Dutch dietary guidelines which include 14 
items: vegetables (≥200 g/day), fruit (≥200 g/day), 
whole-grains (≥90 g/day), legumes (≥135 g/week), 
nuts (≥15 g/day), dairy (≥350 g/day), fish (≥100 g/ 
week), tea (≥450 mL/day), ratio whole-grains:total 
grains (≥50%), ratio unsaturated fats and oils:total 
fats (≥50%), red and processed meat (<300 g/week), 
sugar-containing beverages (≤150 mL/day), alcohol 
(≤10 g/day) and salt (≤6 g/day).38 Adjustment for 
smoking was performed by adjusting for the smoking 
status (never, ever, current).
Statistical analyses
We performed several analyses in order to study the 
association between antimicrobial drug use and the 
composition of the gut microbiota, using several mea-
sures described below. For the diversity, Firmicutes/ 
Bacteroidetes ratio (F/B ratio) and community struc-
ture analysis, we performed two models. In model 1, 
we adjusted for the above-mentioned confounders 
(sex, age, BMI, diabetes, use of co-medication, time 
in the mail and batch number). In model 2, we addi-
tionally adjusted for the categorized use of other anti-
microbial drug groups (thus, for example: the 
association between tetracyclines and the gut micro-
biota was adjusted for the mentioned confounders and 
for categorized use of beta-lactam antibacterials, cate-
gorized use of sulfonamides and trimethoprim, cate-
gorized use of macrolides and lincosamides, 
categorized use of quinolones, and categorized use of 
nitrofuran derivatives). For diet and smoking, the data 
were not available for all participants: 269 (19.0%) 
were missing for diet and 108 (7.6%) for smoking. 
Therefore, adjustment for these confounders was 
only performed in two sensitivity analyses.
Diversity analysis
The Shannon index was used to calculate the alpha- 
diversity (measure of diversity of species within 
a sample). In order to obtain a normal distribution 
(according to the Kolgomorov–Smirnov test), it was 
transformed by calculating the cube. For each antimi-
crobial drug group, a linear regression was performed 
with the transformed Shannon alpha-diversity as the 
dependent variable, and four dummies for 
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antimicrobial drug use of the specific group and the 
confounding variables as independent variables. The 
outcome was back transformed for male gender, 
batch 0, with median age, median BMI, for those who 
had no diabetes, who used no co-medication, of whom 
the sample was a median time in the mail and who used 
no other antimicrobial drugs than the one of interest (= 
average person). P-values <0.05 were considered to be 
significant.
The Firmicutes/Bacteroidetes ratio
The F/B ratio was calculated and logarithmically trans-
formed to obtain a normal distribution. Different linear 
regressions were performed and transformed back to 
the average person as described above but now with as 
a dependent variable the transformed F/B ratio. 
P-values <0.05 were considered to be statistically 
significant.
Community structure analysis
MiRKAT is a recently developed package, available 
in the statistical program R, that tests for associa-
tions between microbiota composition and an out-
come, using a semi-parametric kernel machine 
regression.39 MiRKAT (using 100,000 permutations) 
was used to investigate differences in the composi-
tion of the fecal microbiota using the Bray–Curtis 
beta-diversity distance (measure of dissimilarity of 
species composition between sample pairs). P-values 
<0.05 were considered to be statistically significant.
Single genera analyses
The genera that were significantly different in indivi-
duals who had used antimicrobial drugs were deter-
mined using the MaAsLin (Multivariate Association 
with Linear Models) function.40 The categorized vari-
able for the use of each antimicrobial drug group was 
linearly included in the model (0 for no prescription at 
all, 4 for latest prescription in 0–12 months before 
sampling). For the analysis, the default settings were 
used: a false discovery rate of 25% and q-values <0.05 
were considered to be statistically significant.
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